Associated Papers
N-Terminal Targeting of Regulator of G Protein Signaling Protein 2 for F-Box Only Protein 44-Mediated Proteasomal Degradation.
McNabb HJ et al.
Molecular Pharmacology, 2020
A Global Map of G Protein Signaling Regulation by RGS Proteins.
Masuho I et al.
Cell, 2020
33007266 (PubMed )
Supplement: mmc5.xlsx › RGS2
Loss-of-Function Mutations in Human Regulator of G Protein Signaling RGS2 Differentially Regulate Pharmacological Reactivity of Resistance Vasculature.
Phan HTN et al.
Molecular Pharmacology, 2019
Genetic Analysis of Rare Human Variants of Regulators of G Protein Signaling Proteins and Their Role in Human Physiology and Disease.
Squires KE et al.
Pharmacological Reviews, 2018
Proteolytic degradation of regulator of G protein signaling 2 facilitates temporal regulation of Gq/11 signaling and vascular contraction.
Kanai SM et al.
The Journal of Biological Chemistry, 2017
Human Missense Mutations in Regulator of G Protein Signaling 2 Affect the Protein Function Through Multiple Mechanisms.
Phan HTN et al.
Molecular Pharmacology, 2017
FBXO44-Mediated Degradation of RGS2 Protein Uniquely Depends on a Cullin 4B/DDB1 Complex.
Sjögren B et al.
Plos One, 2015
The RGS2 gene product from a candidate hypertension allele shows decreased plasma membrane association and inhibition of Gq.
Gu S et al.
Molecular Pharmacology, 2008
N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in human embryonic kidney 293 cells.
Bodenstein J et al.
Molecular Pharmacology, 2007
Genetic variations of regulator of G-protein signaling 2 in hypertensive patients and in the general population.
Yang J et al.
Journal of Hypertension, 2005
Select a paper to view details